9OOK | pdb_00009ook

Cryo-EM structure of vaccine-elicited antibody T3_QB_G12 in complex with HIV Env trimer Q23-APEX-GT1


Experimental Data Snapshot

  • Method: ELECTRON MICROSCOPY
  • Resolution: 3.80 Å
  • Aggregation State: PARTICLE 
  • Reconstruction Method: SINGLE PARTICLE 

wwPDB Validation 3D Report Full Report

Validation slider image for 9OOK

This is version 1.1 of the entry. See complete history

Literature

Rapidly acquired HIV-1 neutralization breadth in a rhesus V2 apex knockin mouse model after a single bolus immunization.

Ghosh, A.R.Habib, R.Mishra, N.Roark, R.S.Akauliya, M.Albowaidey, A.A.Allen, J.D.Amereh, K.Avillion, G.Bottermann, M.Liang, B.Chaudhary, N.Callaghan, S.Dye, J.Li, X.Ellis-Pugh, J.R.Roy Chowdhury, R.James, N.E.Liu, X.Maiorino, L.Villavicencio, P.M.Nedellec, R.Oberoi, P.Sowers, K.J.Park, Y.Prum, T.Rodriguez, L.Ssozi, M.Torres, J.L.Walsh, A.A.Warner, J.E.Weldon, S.R.Xu, L.Wiehe, K.Crispin, M.Ward, A.B.Nair, U.Hahn, B.H.Burton, D.R.Shapiro, L.Kwong, P.D.Irvine, D.J.Andrabi, R.Shaw, G.M.Batista, F.D.

(2026) Sci Immunol 11: eadz5064-eadz5064

  • DOI: https://doi.org/10.1126/sciimmunol.adz5064
  • Primary Citation Related Structures: 
    9OOG, 9OOK, 9OOM

  • PubMed Abstract: 

    Current immunization strategies to elicit broadly neutralizing antibodies (bnAbs) against HIV-1 generally propose complex, multiboost regimens. In rhesus macaques, simian-human immunodeficiency virus (SHIV) infection rapidly drives the development of some bnAb classes sharing structural similarities with those in humans. Here, we generated a knockin (KI) mouse model with B cells bearing the unmutated common ancestor of a V2 apex-targeted bnAb lineage, V033-a. A single immunization with a germline-targeting native-like trimer, Q23-APEX-GT1, recapitulated the ontogeny of the mature rhesus bnAb in KI mice, including rare, disfavored somatic mutations. Resulting antibodies exhibited potent neutralization against a broad panel of heterologous HIV-1 strains. Boosting with Env escape mutant trimers further improved breadth and potency, and cryo-electron microscopy analysis revealed the structural basis for heterologous neutralization breadth. Nonhuman primate and mouse models combined with structure can serve as a platform for identifying and validating immunogens that streamline HIV vaccination regimens.


  • Organizational Affiliation
    • Batista Lab, Ragon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA 02139, USA.

Macromolecule Content 

  • Total Structure Weight: 394.75 kDa 
  • Atom Count: 20,928 
  • Modeled Residue Count: 2,430 
  • Deposited Residue Count: 3,312 
  • Unique protein chains: 4

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
T3_QB_G12 heavy chainA [auth H],
E [auth I],
I [auth J]
235Mus musculusMutation(s): 0 
Find similar proteins by:|  3D Structure
Entity ID: 2
MoleculeChains  Sequence LengthOrganismDetailsImage
T3_QB_G12 light chainB [auth L],
F [auth M],
J [auth N]
213Mus musculusMutation(s): 0 
Find similar proteins by:|  3D Structure
Entity ID: 3
MoleculeChains  Sequence LengthOrganismDetailsImage
HIV Env gp120C [auth f],
G [auth h],
K [auth j]
503Homo sapiensMutation(s): 0 
Find similar proteins by:|  3D Structure
Entity ID: 4
MoleculeChains  Sequence LengthOrganismDetailsImage
HIV Env gp41 ectodomainD [auth g],
H [auth i],
L [auth k]
153Homo sapiensMutation(s): 0 

Oligosaccharides

Help  
Entity ID: 5
MoleculeChains Length2D Diagram GlycosylationD Interactions
2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
EA [auth Y],
FA [auth Z],
GA [auth a],
HA [auth b],
IA [auth c],
EA [auth Y],
FA [auth Z],
GA [auth a],
HA [auth b],
IA [auth c],
JA [auth d],
KA [auth e],
LA [auth l],
M [auth A],
MA [auth m],
R [auth F],
RA [auth r],
S [auth G],
SA [auth s],
T [auth K],
TA [auth t],
U [auth O],
UA [auth u],
V [auth P],
VA [auth v],
W [auth Q],
WA [auth w],
X [auth R],
XA [auth x],
Y [auth S],
YA [auth y],
Z [auth T]
2N-Glycosylation
Glycosylation Resources
GlyTouCan: G42666HT
GlyCosmos: G42666HT
GlyGen: G42666HT
Entity ID: 6
MoleculeChains Length2D Diagram GlycosylationD Interactions
beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
AA [auth U],
CA [auth W],
N [auth B],
NA [auth n],
P [auth D],
AA [auth U],
CA [auth W],
N [auth B],
NA [auth n],
P [auth D],
PA [auth p]
3N-Glycosylation
Glycosylation Resources
GlyTouCan: G15407YE
GlyCosmos: G15407YE
GlyGen: G15407YE
Entity ID: 7
MoleculeChains Length2D Diagram GlycosylationD Interactions
alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
BA [auth V],
DA [auth X],
O [auth C],
OA [auth o],
Q [auth E],
BA [auth V],
DA [auth X],
O [auth C],
OA [auth o],
Q [auth E],
QA [auth q]
5N-Glycosylation
Glycosylation Resources
GlyTouCan: G22768VO
GlyCosmos: G22768VO
GlyGen: G22768VO

Small Molecules

Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
NAG

Query on NAG



Download:Ideal Coordinates CCD File
AB [auth f]
AC [auth k]
BB [auth f]
BC [auth k]
CB [auth f]
AB [auth f],
AC [auth k],
BB [auth f],
BC [auth k],
CB [auth f],
CC [auth k],
DB [auth f],
EB [auth f],
FB [auth f],
GB [auth g],
HB [auth g],
IB [auth g],
JB [auth h],
KB [auth h],
LB [auth h],
MB [auth h],
NB [auth h],
OB [auth h],
PB [auth h],
QB [auth i],
RB [auth i],
SB [auth i],
TB [auth j],
UB [auth j],
VB [auth j],
WB [auth j],
XB [auth j],
YB [auth j],
ZA [auth f],
ZB [auth j]
2-acetamido-2-deoxy-beta-D-glucopyranose
C8 H15 N O6
OVRNDRQMDRJTHS-FMDGEEDCSA-N

Experimental Data & Validation

Experimental Data

  • Method: ELECTRON MICROSCOPY
  • Resolution: 3.80 Å
  • Aggregation State: PARTICLE 
  • Reconstruction Method: SINGLE PARTICLE 

Structure Validation

View Full Validation Report



Entry History 

& Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Institutes of Health/National Institute Of Allergy and Infectious Diseases (NIH/NIAID)United States--

Revision History  (Full details and data files)

  • Version 1.0: 2025-11-05
    Type: Initial release
  • Version 1.1: 2026-02-25
    Changes: Data collection, Database references